FDA Approves Imdelltra (tarlatamab-dlle) for Extensive Stage Small Cell Lung Cancer

2024-05-17T11:48:16-05:00May 17th, 2024|Hot Topics, News, Science and Research, Small Cell Lung Cancer|

On May 16, 2024, the U.S. Food and Drug Administration (FDA) granted Imdelltra (tarlatamab-dlle) accelerated approval for people with extensive stage small cell lung cancer (ES-SCLC) following progression on or after platinum-based chemotherapy. The approval is based on results [...]

FDA Approves Alecensa (alectinib) Following Tumor Resection for People with Early-Stage, ALK-Positive Non-Small Cell Lung Cancer

2024-04-19T11:06:35-05:00April 19th, 2024|Hot Topics, News, Science and Research|

Author: Matthew Reiss, MSE, PhD, Manager, Precision Medicine & Navigation, GO2 for Lung Cancer  On April 18, 2024, the U.S. Food and Drug Administration (FDA) approved Alecensa (alectinib) following surgical resection for people living with early-stage ALK-positive non-small cell lung [...]

FDA Approves Tepmetko (tepotinib) for People with Metastatic Non-Small Cell Lung Cancer with MET-Exon 14 Mutation

2024-02-26T16:07:12-06:00February 16th, 2024|Hot Topics, News|

On Feb. 15, 2024, the U.S. Food and Drug Administration (FDA) granted traditional approval of Tepmetko (tepotinib) for people living with metastatic non-small cell lung cancer (NSCLC) with a MET-Exon 14 mutation. Tepmetko (tepotinib) initially received accelerated approval in [...]

FDA Approves Libtayo in Combination with Chemotherapy for Patients with NSCLC Regardless of PD-L1 Status

2022-11-09T14:53:16-06:00November 9th, 2022|Hot Topics, News, Science and Research|

On November 8th, 2022, the Food and Drug Administration (FDA) approved Libtayo (cemiplimab-rwlc) for treatment of non-small cell lung cancer where there are no changes in ALK, EGFR or ROS1 in combination with platinum doublet chemotherapy. The FDA based [...]

FDA Approves Rybrevant as First Targeted Treatment for Patients with NSCLC with EGFR Exon 20 Insertion Mutations

2021-05-24T13:00:46-05:00May 24th, 2021|Hot Topics, News, Science and Research|

On May 21st, 2021, the Food and Drug Administration (FDA) approved Rybrevant (amivantamab-vmjw) for treatment of advanced non-small cell lung cancer (NSCLC) with a change in EGFR called exon 20 insertion. The FDA based their approval on the results of [...]

Go to Top